Cardiac resynchronization therapy contraindications

Jump to navigation Jump to search

Cardiac resynchronization therapy Microchapters

Home

Overview

Indications

Landmark Trials

Contraindications

Pathophysiologic Basis for CRT

Treatment

Preoperative Evaluation

Procedure

Recovery

Outcomes and Prognosis

Complications

Cardiac resynchronization therapy contraindications On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac resynchronization therapy contraindications

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac resynchronization therapy contraindications

CDC on Cardiac resynchronization therapy contraindications

Cardiac resynchronization therapy contraindications in the news

Blogs on Cardiac resynchronization therapy contraindications

Directions to Hospitals Administering Cardiac resynchronization therapy

Risk calculators and risk factors for Cardiac resynchronization therapy contraindications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief:: Bhaskar Purushottam, M.D. [2] Synonyms and Keywords: CRT

Overview

CRT is contraindicated in patients who are asymptomatic or who have a limited life expectancy.

Contraindications

  • Patients who are asymptomatic with a reduced LVEF who have no other indications for pacing.
  • Patients who have a limited life expectancy due to a non-cardiac condition.
  • Patients who have a limited functional capacity due to a chronic non-cardiac condition.

ACC / AHA Guidelines - Recommendations for Cardiac Resynchronization Therapy in Patients with Severe Systolic Heart Failure (DO NOT EDIT)[1]

Class III

1) CRT is not indicated for asymptomatic patients with reduced LVEF in the absence of other indications for pacing. (Level of Evidence: B)

2) CRT is not indicated for patients whose functional status and life expectancy are limited predominantly by chronic noncardiac conditions.(Level of Evidence: C)


References

  1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW (2008). "ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons". Circulation. 117 (21): e350–408. doi:10.1161/CIRCUALTIONAHA.108.189742. PMID 18483207. Retrieved 2011-01-15. Unknown parameter |month= ignored (help)

Template:WH Template:WS